<DOC>
	<DOCNO>NCT00245505</DOCNO>
	<brief_summary>The purpose study visualize heal effect mucosal lesion Pentasa Sachet 4g patient mild moderate active small bowel CD video capsule endoscopy .</brief_summary>
	<brief_title>The Effect Mucosal Healing With Pentasa Sachet Mild Moderate Active `` Drug : Crohn 's Disease ''</brief_title>
	<detailed_description>The purpose study visualize heal effect mucosal lesion Pentasa Sachet 4g patient mild moderate active small bowel CD video capsule endoscopy</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>4.2 Inclusion Criteria 1 . Patients sign informed consent form 2 . Patients perform complete VCE &lt; 7 day prior inclusion diagnose clinically active mild moderate small bowel CD stricture previous examination , previously proven barium small bowel follow , enteroclysis / patency test capsule . 3 . Patients 18 70 year age . 4.3 Exclusion Criteria 1 . Patients evidence form inflammatory small bowel bowel disease , idiopathic proctitis infectious disease . 2 . Patients know small bowel stricture previous examination instance barium small bowel follow , enteroclysis / patency capsule test . 3 . Patients pacemaker due lack VCE interaction data . 4 . Patients undergo study procedure due swallow disorder . 5 . Planned actual pregnancy lactation . 6 . Women childbearing potential use effective method contraception , opinion investigator . 8 . Patients receive maintenance treatment ( p.o . ) total daily dose 2.0g sulphasalazine , mesalazine 4ASA , 30 day prior entry study . 9 . Chronic use nonsteroidal antiinflammatory drug ( oral and/or rectal route ) 30 day prior inclusion study ( chronic use define drug intake minimum 3 consecutive day ) . 10 . Intake corticosteroid ( oral and/or rectal route ) within 30 day prior enrolment study . 11 . Patients receive immunosuppressive ( azathioprine , 6MP , etc ) agent 30 day prior study enrolment . 12 . Patients receive Crohn specific biological agent ( TNFalfa ) last year prior study enrolment . 13 . Patients disease condition may interfere study assessment judge investigator . 14 . Alcoholism drug addiction . 15 . Patients participate participate another clinical study previous 30 day . 16 . Patients severe renal/hepatic impairment ( see section 5.6 ) judge investigator . 17 . Patients allergic salicylate 5ASA derivative . 18 . Patients unlikely comply protocol . 19 . Any patient previously take part study . 20 . Patients unable write read local language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>